Clinical trials: Venous Thromboembolic Event
Hip Arthroplasty, Total, Prevention of Venous Thromboembolism
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly…
- Trial name
- ENABLE-Hip (NCT06611319)
- Testing
- Prevention of Venous Thromboembolism
- Where
- 6 sites in Austria, Germany
- Volunteers
- 2,932 people
- Sponsor
- Prof. Stavros Konstantinides, MD
Cerebral Venous Sinus Thrombosis
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were…
- Trial name
- NCT06551402
- Testing
- Dabigatran Etexilate 150mg, Rivaroxaban 20 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
Simulation, Venous Thromboembolism
Pregnancy and Postpartum Period Venous Thromboembolism and Simulation
This research will be carried out to determine the effectiveness of teaching thromboembolism risk assessment during pregnancy and postpartum period to midwifery students using a high-tech simulation method.
- Trial name
- NCT06218095
- Testing
- Simulation application
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
COVID-19, Venous Thromboembolism
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
Study purpose was to study the safety and efficacy of Dimolegin - DD217 as a drug for prevention of thrombotic complications compared to Clexane (enoxaparin sodium) - the standard therapy currently prescribed to patients…
- Trial name
- NCT05185804
- Testing
- Dimolegin, Clexane
- Where
- 6 sites in Russia
- Volunteers
- 399 people
- Sponsor
- PharmaDiall Ltd.
Venous Thrombosis, End Stage Renal Failure With Renal Transplant
The Risk of Venous Clotting in Patients After Renal Transplant
Clots that develop in the deep veins of the legs or the lungs can result in pain, heart and lung disease and may lead to death if unrecognized or not treated.
- Conditions
- Venous Thrombosis, End Stage Renal Failure With Renal Transplant, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- REPORT (NCT01413464)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Pulmonary Embolism, Venous Thromboembolism
Prognostic Value of 2026 AHA/ACC Clinical Categorization in Acute Pulmonary Embolism Patients Presenting to the Emergency Department
Background: The 2026 American Heart Association/American College of Cardiology (AHA/ACC) Pulmonary Embolism Guideline (Creager et al., Circulation 2026) introduced a novel five-category (A-E) clinical classification system with…
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Acute Pulmonary Embolism
- Trial name
- APEX-2026 (NCT07805616)
- Testing
- 2026 AHA/ACC Clinical Risk Categorization
- Where
- Turkey (Türkiye)
- Volunteers
- 600 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Venous Thromboembolism
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge.
- Trial name
- DC-eALERT (NCT03728166)
- Testing
- Electronic alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Neoplasms Malignant, Surgery
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer.
- Conditions
- Neoplasms Malignant, Surgery, Venous Thromboembolism, Prophylaxis
- Trial name
- NCT04479579
- Testing
- Apixaban 2.5 milligram
- Where
- 2 sites in Canada
- Volunteers
- 53 people
- Sponsor
- McMaster University
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Deep Venous Thrombosis, Pulmonary Embolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
The purpose of this study is to demonstrate the ability of STA® Liatest® D-Di combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism (PE) or Deep Venous Thrombosis (DVT) in a 3 month follow-up.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, D-dimer
- Trial name
- DiET (NCT01221805)
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 2,040 people
- Sponsor
- Diagnostica Stago
Venous Thromboembolism
High-Risk Factors for VTE Death
Study population and characteristics This retrospective cohort study initially screened 105,168 consecutive hospitalized patients at Shihezi People's Hospital from February 2022 to June 2025.
- Trial name
- NCT07767279
- Testing
- comorbidity, Respiratory Failure, Sepsis
- Where
- China
- Volunteers
- 105,168 people
- Sponsor
- China International Neuroscience Institution
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Incisional Hernia, Venous Thromboembolism
Risk Factors of Venous Thromboembolism After Incisional Ventral Hernia Repair.
Aim of our study is to find frequency and risk factors for venous thromboembolism development in patients who underwent surgery for incisional ventral hernia.
- Trial name
- NCT05439187
- Testing
- hernia repair
- Where
- Russia
- Volunteers
- 240 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolic Disease
Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first…
- Trial name
- NCT03887806
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Venous Thromboembolism
Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
The aim of this study is to evaluate the efficacy and safety of individual dose adjustment of low molecular weight heparin (LMWH) based on the results of the thrombodynamics test (TD) in patients at extremely high risk of…
- Trial name
- IDAHeT (NCT04710732)
- Testing
- Standard Enoxaparin 40 mg once-daily before randomization, Standard Enoxaparin 40 mg once-daily after randomization, Escalated Enoxaparin 30 mg twice-daily after randomization
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Pirogov Russian National Research Medical University
Thromboembolism
Secondary Prevention of Venous Thrombo Embolism (VTE).
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and…
- Trial name
- RE-MEDY (NCT00329238)
- Testing
- Dabigatran, Warfarin
- Where
- 275 sites in United States, Argentina and 31 more
- Volunteers
- 2,867 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Venous Thromboembolism (VTE) Knowledge
Venous thromboembolism (VTE) is common especially among post-operative patients, and its occurrence is associated with significant morbidity and mortality.
- Trial name
- NCT05548010
- Testing
- No intervention as this is an observational study
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong